Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 21, Issue 2, pp 167–174 | Cite as

Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions

  • Katie M. Twomley
  • Sunil V. Rao
  • Richard C. BeckerEmail author
Perspectives

Abstract

For many years, the traditional treatment for hospitalized patients in the United States who have developed anemia, whether associated with medical illness, surgical procedures or trauma, has been red blood cell transfusion, despite the absence of supporting data in many patient populations. Emerging evidence suggests that transfusions may, in fact, be associated with risk beyond commonly held concerns of microbial transmission and acute antigen-antibody reactions. The following overview represents a biological paradigm for understanding the relationship between medical illness, surgical procedures, inflammatory states, anemia, red blood cell transfusion and immunothrombotic phenomena among hospitalized patients.

Keywords

Anemia Thrombosis Transfusion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rodriguez RM, Corwin HL, Getteinger A, Corwin MJ, Gubler D, Pearl RG (2001) Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 16:36–41PubMedCrossRefGoogle Scholar
  2. 2.
    Poveda Gomez F, Camacho Siles J, Quevedo Morales E, et al. (2001) Pattern of blood levels of erythropoietin and proinflammatory cytokines in patients with anemia of chronic disease secondary to infection. Ann Med In 18:298–304Google Scholar
  3. 3.
    Corwin HL, Krantz SB (2000) Anemia of the critiacally ill: “acute” anemia of chronic disease. Crit Care Medicine 28:3098–3099CrossRefGoogle Scholar
  4. 4.
    Andre P, Prasad KS, Denis CV, et al. (2002) CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nature Medicine 8;247–252PubMedCrossRefGoogle Scholar
  5. 5.
    Aukrust P, Muller F, Ueland T, et al. (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620PubMedCrossRefGoogle Scholar
  6. 6.
    Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS (2002) Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 106:2372–2378PubMedCrossRefGoogle Scholar
  7. 7.
    Devaraj S, Xu DY, Jialal I (2003) C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107:398–404PubMedCrossRefGoogle Scholar
  8. 8.
    Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106:491–496PubMedCrossRefGoogle Scholar
  9. 9.
    Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394:200–203PubMedCrossRefGoogle Scholar
  10. 10.
    Schafer K, Muller K, Hecke A, et al. (2003) Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscl, Thromb Vasc Biol 23:2097–2103CrossRefGoogle Scholar
  11. 11.
    Schonbeck U, Mach F, Sukhova GK, et al. (1997) Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by t lymphocytes. Circ Res 81:448–454Google Scholar
  12. 12.
    Siren V, Kauhanen P, Carpen O, et al. (2003) Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Blood Coag Fibrinol 14:369–377CrossRefGoogle Scholar
  13. 13.
    Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106:981–986PubMedCrossRefGoogle Scholar
  14. 14.
    Levy PS, Kim SJ, Eckel PK, et al. (1993) Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 265:H340–H349PubMedGoogle Scholar
  15. 15.
    Taylor JE, Henderson IS, Stewart WK, Belch JJ (1991) Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 338;1361–1362PubMedCrossRefGoogle Scholar
  16. 16.
    Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548Google Scholar
  17. 17.
    Carson JL, Duff A, Poses RM, et al. (1996) Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 348:1055–1060PubMedCrossRefGoogle Scholar
  18. 18.
    Carson JL, Noveck H, Berlin JA, Gould SA (2002) Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 42:812–818PubMedCrossRefGoogle Scholar
  19. 19.
    Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer; a systematic review of the literature. Am J Med 116(Suppl 7A):11S–26SGoogle Scholar
  20. 20.
    Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure; the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41:1933–1939PubMedCrossRefGoogle Scholar
  21. 21.
    Corwin HL, Gettinger A, Pearl RG, et al. (2004) the CRIT Study. Anemia and blood transfusion in the critically ill–-current clinical practice in the United States. Crit Care Med 32:39–52PubMedCrossRefGoogle Scholar
  22. 22.
    Adam RC, Lundy JS (1942) Anesthesia in cases of poor risk: Some suggestion for decreasing the risk. Surg Gynocol Obstet 74:1011–1101Google Scholar
  23. 23.
    Shander A (2004) Anemia in the critically ill. Crit Care Clin 20:159–178PubMedCrossRefGoogle Scholar
  24. 24.
    Carson JL, Duff A, Berlin JA, Lawrence VA, Poses RM, Huber EC, O’Hara DA, Noveck H, Strom BL (1998) Perioperative blood transfusion and postoperative mortality. JAMA 279:199–205PubMedCrossRefGoogle Scholar
  25. 25.
    Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM (2001) Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345:1230–1236PubMedCrossRefGoogle Scholar
  26. 26.
    Hebert PC, Yetisir E, Martin C, et al. (2001) Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 29:227–234PubMedCrossRefGoogle Scholar
  27. 27.
    Rao SV, Jollis JG, Harrington RA, et al. (2004) Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary Syndromes. JAMA 292:1555–1562PubMedCrossRefGoogle Scholar
  28. 28.
    Hebert PC, Wells G, Blajchman MA, et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340:409–417PubMedCrossRefGoogle Scholar
  29. 29.
    Malone DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54:898–907PubMedCrossRefGoogle Scholar
  30. 30.
    Vincent JL, Baron JF, Reinhart K, et al. (2002) ABC (Anemia and Blood Transfusion in Critical Care) Investigators. Anemia and blood transfusion in critically ill patients. JAMA 288:1499–1507PubMedCrossRefGoogle Scholar
  31. 31.
    Blumberg N (1997) Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol 34(3 Suppl 2):34–40Google Scholar
  32. 32.
    Anderson CB, Tyler JD, Rodey GE, et al. (1987) Peroperative immunomodulation of renal allograft recipients by concomitant immunosuppression and donor-specific transfusions. Transplant Proc. 19(1 Pt 2):1494–1497PubMedGoogle Scholar
  33. 33.
    Karamloiu T, Schultz JM, Silliman C, et al. (2005) Using a miniaturized circuit and an asanguineous prime to reduce neutrophil-mediated organ dysfunction following infant cardiopulmonary bypass. Ann Thorac Surg 80(1):6–13; discussion 13–14Google Scholar
  34. 34.
    Toy P, Popovsky MA, Abraham E. et al. (2005) National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 33(4)721–726PubMedCrossRefGoogle Scholar
  35. 35.
    Silliman CC, Ambruso DR, Boshkov LK (2005) Transfusion-related acute lung injury. Blood 105(6):2266–2273PubMedCrossRefGoogle Scholar
  36. 36.
    Vamvakas EC (2002) Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Transfusion Med Rev 16:304–314CrossRefGoogle Scholar
  37. 37.
    Ho J, Sibbald WJ, Chin-Yee IH (2003) Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 31(12 Suppl):S687–S697Google Scholar
  38. 38.
    Nielsen HJ, Edvardsen L, Brunner N, et al. (1996) Time-dependent, spontaneous release of leukocyte and platelet derived bioactive substances from stored human blood. Transfusion 36:960–965PubMedCrossRefGoogle Scholar
  39. 39.
    van de Watering LM, Hermans J, Houbiers JG, et al. (1998) Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 97:562–568PubMedCrossRefGoogle Scholar
  40. 40.
    Biedler AE, Schneider SO, Seyfert U, et al. (2002) Impact of alloantigens and storage-asssociated factors on stimulated cytokine response in an in vitro model of blood transfusion. Anesthesiology 97:1102–1109PubMedCrossRefGoogle Scholar
  41. 41.
    Klein HG (2003) Getting older is not necessarily getting better. Anesthesiology 98:807–808PubMedCrossRefGoogle Scholar
  42. 42.
    Sparrow RL, Patton KA (2004) Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion 44:722–730PubMedCrossRefGoogle Scholar
  43. 43.
    Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268PubMedCrossRefGoogle Scholar
  44. 44.
    Sabovic M, Zorman SK (2003) Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. Heart Vessels 18:47–49PubMedCrossRefGoogle Scholar
  45. 45.
    Nielsen HJ, Reimert C, Pedersen AN, et al. (1997) Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 78:548–552PubMedCrossRefGoogle Scholar
  46. 46.
    Hedstrom M, Flordal PA, Ahl T, Svensson J, Dalen N (1996) Autologous blood transfusion in hip replacement. No effect on blood loss but less increase of plasminogen activator inhibitor in a randomized series of 80 patients. Acta Orthop Scand 67:317–320PubMedCrossRefGoogle Scholar
  47. 47.
    Pawloski JR, Stamler JS (2002) Nitric oxide in RBCs. Transfusion 42:1603–1609PubMedCrossRefGoogle Scholar
  48. 48.
    Bor-Kucukatay M, Wenby RB, Meiselman HJ, Baskurt OK (2003) Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol 284:H1577–1584PubMedGoogle Scholar
  49. 49.
    Tsai AG, Cabrales P, Intaglietta M (2004) Microvascular perfusion upon exchange transfusion with stored red blood cells in normovolemic anemic conditions. Transfusion 44:1626–1634PubMedCrossRefGoogle Scholar
  50. 50.
    Xiao Z, Theroux P (2004) Clopidogrel inhibits platelet-leukocyte interaction and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 43:1982–1988PubMedCrossRefGoogle Scholar
  51. 51.
    Tinmouth A, Macdougall L, Fergusson D, et al. Reducing the amount of blood transfused: a systematic review of behavioral interventions to change physicians’ transfusion practices.Google Scholar
  52. 52.
    Eindhoven GB, Diercks RL, Richardson FJ, et al. (2005) Adjusted transfusion triggers improve transfusion practice in orthopaedic surgery. Transfus Med 15(1):13–18PubMedCrossRefGoogle Scholar
  53. 53.
    Wautier JL, Cabaud JJ, Cazenave JP, et al. (2005) College des enseignants en transfusion sanguine. [French training program for medical students in transfusion medicine. Transfusion Medicine Teachers’ College]. Transfus Clin Biol 12(1):59–69PubMedCrossRefGoogle Scholar
  54. 54.
    Hervig T, Flesland O, Svenningsen V, Bosnes V (2004) Guidelines for transfusion in Norway. Transfus Apheresis Sci 3198:181–184CrossRefGoogle Scholar
  55. 55.
    Potocnik M (2005) Transposing the E.E.U. Blood directive into national law. Perspective of Slovenia. Transfus Clin Biol 12(1):21–24PubMedCrossRefGoogle Scholar
  56. 56.
    Dickinson T, Riley J, Steg A, Zabetakis P (2004) Observations from a national multiple institution autotransfusion (ATS) quality indicator program. J Extra Corpor Technol 36(2):153–157PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Katie M. Twomley
    • 1
  • Sunil V. Rao
    • 1
  • Richard C. Becker
    • 1
    Email author
  1. 1.Department of Medicine, Duke University Medical Center, Cardiovascular Thrombosis CenterDuke Clinical Research InstituteDurham

Personalised recommendations